Tenpoint Therapeutics, Ltd. is a global commercial biotech company focused on rejuvenating vision in the aging eye. Its lead product, YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution 2.75% / 0.1%), is the first and only dual-agent eye drop approved for presbyopia, a condition that affects about 128 million people in the United States and roughly 2 billion worldwide. The company plans to launch YUVEZZI in early Q2, supported by a leadership team with extensive ophthalmology experience. Tenpoint emphasizes real-world needs by partnering closely with eye-care professionals to bring innovative treatments to market. Financially, the firm recently bolstered its balance sheet with $85 million in Series B equity financing and a $150 million non-dilutive term loan facility, bringing in both new and existing blue-chip investors. This capital positions Tenpoint to execute a large-scale commercial rollout while continuing to build its pipeline of therapies for the aging eye.

Total raised

$305M

Funding rounds

3

Latest round

Series B

Latest activity

Jan 2026